Constant Contact, Inc. - FORM 10-Q - EX-32.2 - August 4, 2010



Attached files
FileFilename
10-Q - FORM 10-Q - Constant Contact, Inc.b81949e10vq.htm
EX-31.1 - EX-31.1 - Constant Contact, Inc.b81949exv31w1.htm
EX-10.1 - EX-10.1 - Constant Contact, Inc.b81949exv10w1.htm
EX-31.2 - EX-31.2 - Constant Contact, Inc.b81949exv31w2.htm
EX-10.2 - EX-10.2 - Constant Contact, Inc.b81949exv10w2.htm
EX-32.1 - EX-32.1 - Constant Contact, Inc.b81949exv32w1.htm
         
Exhibit 32.2
CERTIFICATION OF THE CHIEF FINANCIAL OFFICER PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report on Form 10-Q for the quarterly period ending June 30, 2010 of Constant Contact, Inc. (the “Company”), as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Harpreet Grewal, Executive Vice President and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to my knowledge, that:
  (1)   The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
 
  (2)   The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
         
     
Date: August 4, 2010  /s/ Harpreet S. Grewal    
  Harpreet S. Grewal   
  Executive Vice President and
Chief Financial Officer 
 
 

User Contributions:

Comment about this document or add new information about this topic:

CAPTCHA



This web site and associated pages are not associated with, endorsed by, or sponsored by Constant Contact, Inc. and has no official or unofficial affiliation with Constant Contact, Inc.


Based on public records. Inadvertent errors are possible.
Faqs.org does not guarantee the accuracy or timeliness of any information on this site.  Use at your own risk. This website is not associated with the SEC

Some parts © 2013 Advameg, Inc.